Two-Year Clinical and Radiographic Results With Combination Etanercept-Methotrexate Therapy Versus Monotherapy in Early Rheumatoid Arthritis
Two-Year Clinical and Radiographic Results With Combination Etanercept-Methotrexate Therapy Versus Monotherapy in Early Rheumatoid Arthritis
复制标题
DOI：
10.1002/art.27268
复制
发表时间：
2010-03-01
影响因子：
--
通讯作者：
Freundlich, Bruce
中科院分区：
文献类型：
--
作者：
Emery, Paul;Breedveld, Ferdinand;Freundlich, Bruce
客观的。旨在评估初始第一年依那西普-甲氨蝶呤 (MTX) 联合治疗和 MTX 单药治疗方案的继续和改变如何影响早期活动性类风湿关节炎的长期缓解和影像学进展。方法。在整个 2 年期间，受试者在基线时被随机分配；完成 1 年联合治疗或 MTX 单药治疗的患者进入第 2 年。最初的联合治疗组在第 2 年继续联合治疗（EM/EM 组；n = 111）或接受依那西普单药治疗（EM/E 组；n = 111）；最初的 MTX 单药治疗组在第 2 年接受联合治疗（M/EM 组；n = 90）或继续单药治疗（M/M 组；n = 99）。疗效终点包括缓解（28 个关节的疾病活动评分 [DAS28] < 2.6）和放射学无进展（改良 Sharp/van der Heijde 评分的变化）
Objective. To evaluate how continuation of and alterations to initial year 1 combination etanercept-methotrexate (MTX) therapy and MTX monotherapy regimens affect long-term remission and radiographic progression in early, active rheumatoid arthritis.Methods. Subjects were randomized at baseline for the entire 2-year period; those who completed 1 year of treatment with combination or MTX monotherapy entered year 2. The original combination group either continued combination therapy (the EM/EM group; n = 111) or received etanercept monotherapy (the EM/E group; n = 111) in year 2; the original MTX monotherapy group either received combination therapy (the M/EM group; n = 90) or continued monotherapy (the M/M group; n = 99) in year 2. Efficacy end points included remission (a Disease Activity Score in 28 joints [DAS28] < 2.6) and radiographic nonprogression (change in the modified Sharp/van der Heijde score